Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Lexaria Bioscience Corp. (LXRP)

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Technology Revolutionizes CBD Delivery

Posted on April 5, 2019 by MissionIR

Biotechnology company Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative drug-delivery platform DehydraTECH(TM) alters the way cannabinoids enter the bloodstream, which results in increased absorption. A recent article discussing LXRP reads, “Its proprietary technology promises multiple advantages in cannabinoid edibles. First, … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Talks DehydraTECH’s Lifesaving Technology on CEO Clips

Posted on April 5, 2019 by MissionIR

LXRP CEO Chris Bunka explained in the interview that proprietary technology can save 60,000 lives annually if consumption habits of even one percent of smokers worldwide change CEO Clips videos are featured on business sites including BNN Bloomberg, Thomson Reuters, … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Launches Its Largest Cannabinoid Research Program

Posted on April 1, 2019 by MissionIR

The R&D program will focus on the proprietary Lexaria DehydraTECH delivery technology with the purpose of enhancing it further Results could contribute to new patent filings in the future; in addition, the program will examine more extensively the way DehydraTECH-enabled … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Utilizes Disruptive Technology for Improved Delivery of Bioactive Compounds

Posted on March 29, 2019 by MissionIR

Biotechnology company and drug-delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTC: LXRP) utilizes disruptive technology for the improved delivery of bioactive compounds. A recent article discussing this reads, “Lexaria’s technology has been shown to be effective in numerous global studies, … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Revolutionary Technology is Disrupting the Cannabis Edibles Industry

Posted on March 26, 2019 by MissionIR

Lexaria Bioscience Corp. is the only company worldwide with patents issued for oral delivery of all cannabinoids Its proprietary technology bests traditional methods such as inhalation in several key ways The company continues to enhance its intellectual property portfolio as … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Launches its Largest Cannabinoid R&D Program

Posted on March 21, 2019 by MissionIR

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTC: LXRP) on Wednesday announced that work has commenced on its largest-ever cannabinoid research program, which will also test Lexaria-designed nanotech enhancements. According to the update, the new program … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Conduct Further Human Clinical Trials Following Positive TurboCBD Results

Posted on March 12, 2019 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) plans to conduct additional clinical trials using DehydraTECH(TM) in CBD after recently reporting noteworthy results of cardiovascular performance improvements with TurboCBD. A recent article discussing the company reads, “TurboCBD is Lexaria’s proprietary DehydraTECH-powered, CBD-fortified … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Innovating on Numerous Fronts with DehydraTECH Drug Delivery Platform

Posted on March 12, 2019 by MissionIR

Lexaria Bioscience is focusing on its unique technology for the delivery of bioactive compounds The company’s concentration on oral ingestion results in an option that often healthier than other delivery methods Its DehydraTECH technology has potential applications for nicotine absorption … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Conduct Clinical Studies on Oral Nicotine Delivery Utilizing DehydraTECH Absorption Platform

Posted on March 4, 2019 by MissionIR

Lexaria Nicotine LLC, a subsidiary of Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), recently secured research and development (“R&D”) funding in exchange for equity and licensing rights. Utilizing its DehydraTECH absorption platform, Lexaria will execute a wide-ranging series of clinical studies … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Supports Recent FDA Statement on Novel Nicotine Replacement Therapies

Posted on February 26, 2019 by MissionIR

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning conveyed its support for the Food & Drug Administration’s (“FDA”) February 21 statement titled “Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products”. … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment